Baricitinib for severe childhood hair loss from alopecia areata
Treatments studied
Part of Skin clinical trials.
This trial tests whether baricitinib can improve severe alopecia areata (patchy, autoimmune hair loss) in children and teens. It’s meant for people who have had long-lasting, severe hair loss and have tried other treatments without enough benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 6 and under 18 years old
- Your alopecia areata has been severe for at least 1 year and you were diagnosed at least 1 year ago
- Your current hair-loss episode has lasted at least 6 months
- Your scalp hair-loss level is severe on the study scale (SALT score 50% or higher)
- You’ve tried at least one earlier treatment for alopecia areata (like creams or other options) and it didn’t work well
- You do not have certain other causes of hair loss (like diffuse shedding) or other scalp/medical problems that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This study tests two different doses of a pill called ritlecitinib to see if it can help regrow hair in people with significant hair loss from alopecia areata. It is for people aged 12 and older who have lost at least half of their scalp hair.
This study tests an investigational oral medication (deuruxolitinib) for adolescents with severe alopecia areata (hair loss). It aims to see if it can help hair regrow safely.
This study follows people with alopecia areata who are starting treatment with ritlecitinib (a medication). It looks at how well the treatment works in real life and how it affects your symptoms and quality of life.
This study tests a pill called baricitinib for people with active alopecia areata that started within the last 3 months. Baricitinib is a type of medication called a JAK inhibitor, which can help calm the immune system and stop hair loss.
This study tests if upadacitinib can help young people with severe alopecia areata (a condition causing patchy hair loss) regrow their hair. It may be an option if hair loss has been present for less than 8 years and there has been no recent improvement.
Hear when a new Alopecia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.